Sanchez-Luna, M. Burgos-Pol, R. Oyagüez, I. Figueras-Aloy, J. Sánchez-Solís, M. Martinón-Torres, F. Carbonell-Estrany, X. Additional file 1: Figure S1. of Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain Curve fitting to get the palivizumab effect on recurrent wheezing over 61 years by using RR values from the literature. (DOCX 19 kb) Cost-effectiveness;Preterm infants;Palivizumab;RSV infection;Recurrent wheezing 2017-10-17
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Figure_S1_of_Cost-utility_analysis_of_Palivizumab_for_Respiratory_Syncytial_Virus_infection_prophylaxis_in_preterm_infants_update_based_on_the_clinical_evidence_in_Spain/5509060
10.6084/m9.figshare.c.3907168_D1.v1